Skip to main content
SpringerLink
Log in

Plasminogen Activators Inhibitors

  • Chapter
Book cover Plasminogen: Structure, Activation, and Regulation

Abstract

The activation of the fibrinolytic system occurs when plasminogen is converted into plasmin by plasminogen activators (PA) such as tissue-type plasminogen activator (t-PA) and urokinase-type plasminogen activator (u-PA). Inhibition of the fibrinolytic system may occur through inhibition of these plasminogen activators by plasminogen activator inhibitors (PAIs) or through inhibition of plasmin by α2-antiplasmin. In this chapter, the PAIs are discussed. The two most important PAIs are PAI-1 and PAI-2 (Loskutoff et al., 1983; Lecander and Astedt, 1986). In urine, a complex of u-PA and an inhibitor was found and, therefore, this inhibitor was named PAI-3, which was subsequently found to be identical to the protein C inhibitor (PCI) (Stump et al., 1986; Heeb et al., 1987).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Abrahamsson T., Nerme V., Stromqvist M., Akerblom B., Legnehed A., Pettersson K., and Westin Eriksson A. (1996). Anti-thrombotic effect of a PAI-1 inhibitor in rats given endotoxin.Thromb. Haemost. 75, 118–126.

    PubMed  CAS  Google Scholar 

  • Aertgeerts K., De Bondt H.L., De Ranter C.J., and Declerck P.J. (1995). Mechanisms contributing to the conformational and functional flexibility of plasminogen activator inhibitor-1.Nat. Struct. Biol. 2, 891–897.

    Article  PubMed  CAS  Google Scholar 

  • Alessi M.C., Declerck P.J., De Mol M., Nelles L., and Collen D. (1988). Purification and characterization of natural and recombinant human plasminogen activator inhibitor-1 (PAI-1).Eur. J. Biochem. 175, 531–540.

    Article  PubMed  CAS  Google Scholar 

  • Alessi M.C., Peiretti F., Morange P., Henry M., Nalbone G., and Juhan-Vague I. (1997). Production of plasminogen activator inhibitor 1 by human adipose tissue: Possible link between visceral fat accumulation and vascular disease.Diabetes 46, 860–867.

    Article  PubMed  CAS  Google Scholar 

  • Andreasen PA., Egelund R., Jensen S., and Rodenburg K.W. (1999). Solvent effects on activity and conformation of plasminogen activator inhibitor-1.Thromb. Haemost. 81, 407–414.

    PubMed  CAS  Google Scholar 

  • Andreasen P.A., Kjoller L., Christensen L., and Duffy M.J. (1997). The urokinase type plasminogen activator system in cancer metastasis: A review.Int. J. Of Cancer 72, 1–22.

    Article  CAS  Google Scholar 

  • Andreasen P.A., Nielsen L.S., Kristensen P., Grondahl Hansen J., Skriver L., and Dano K. (1986). Plasminogen activator inhibitor from human fibrosarcoma cells binds urokinase-type plasminogen activator, but not its proenzyme.J. Biol. Chem. 261, 7644–7651.

    PubMed  CAS  Google Scholar 

  • Audenaert A.M., Knockaert I., Collen D., and Declerck P.J. (1994). Conversion of plasminogen activator inhibitor-1 from inhibitor to substrate by point mutations in the reactive-site loop.J. Biol. Chem. 269, 19559–19564.

    PubMed  CAS  Google Scholar 

  • Bennett W.F., Paoni N.F., Keyt B.A., Botstein D., Jones A.J., Presta L., Wurm F.M., and Zoller M.J. (1991). High resolution analysis of functional determinants on human tissue-type plasminogen activator.J. Biol. Chem. 266, 5191–5201.

    PubMed  CAS  Google Scholar 

  • Berry C.N., Lunven C., Lechaire I., Girardot C., and OConnor S.E. (1998). Antithrombotic activity of a monoclonal antibody inducing the substrate form of plasminogen activator inhibitor type 1 in rat models of venous and arterial thrombosis.Br. J. Pharmacol 125, 29–34.

    Article  PubMed  CAS  Google Scholar 

  • Biemond B.J., Levi M., Coronel R., Janse M.J., ten Cate J.W., and Pannekoek H. (1995). Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis. Effects of a plasminogen activator inhibitor type 1-neutralizing monoclonal antibody.Circulation 91, 1175–1181.

    Article  PubMed  CAS  Google Scholar 

  • Bijnens A.P., Gils A., Knockaert I., Stassen J.M., and Declerck P.J. (2000). Importance of the hinge region between α-helix F and the main part of serpins, based upon identification of the epitope of plasminogen activator inhibitor type 1 neutralizing antibodies.J. Biol. Chem. 275, 6375–6380.

    Article  PubMed  CAS  Google Scholar 

  • Bijnens A.P., Gils A., Stassen J.M., Komissarov A.A., Knockaert I., Brouwers E., Shore J.D., and Declerck P.J. (2001). The distal hinge of the reactive site loop and its proximity: a target to modulate plasminogen activator inhibitor-1 activity.J. Biol. Chem. 276, 44912–44918.

    Article  PubMed  CAS  Google Scholar 

  • Bijnens A.P., Knockaert I., Cousin E., Kruithof E.K., and Declerck P.J. (1997). Expression and characterization of recombinant porcine plasminogen activator inhibitor-1.Thromb. Haemost. 77, 350–356.

    PubMed  CAS  Google Scholar 

  • Billingsley G.D., Walter M.A., Hammond G.L., and Cox D.W. (1993). Physical mapping of four serpin genes: Alpha 1-antitrypsin, alpha 1-antichymotrypsin, corticosteroid-binding globulin, and protein C inhibitor, within a 280-kb region on chromosome I4q32.1.Am. J. Hum. Genet. 52, 343–353.

    PubMed  CAS  Google Scholar 

  • Bjorquist P., Ehnebom J., Inghardt T., and Deinum J.R. (1997). Epitopes on plasminogen activator inhibitor type 1 important for binding to tissue plasminogen activator.Biochim. Biophys. 1341, 87–98.

    Article  CAS  Google Scholar 

  • Bjorquist P., Ehnebom J., Inghardt T., Hansson L., Lindberg M., Linschoten M., Stromqvist M., and Deinum J. (1998). Identification of the binding site for a low-molecular-weight inhibitor of plasminogen activator inhibitor type 1 by site- directed mutagenesis.Biochemistry 37, 1227–1234.

    Article  PubMed  CAS  Google Scholar 

  • Bone R.C. (1992). Modulators of coagulation. A critical appraisal of their role in sepsis.Arch. Intern. Med. 152, 1381–1389.

    Article  PubMed  CAS  Google Scholar 

  • Booth N.A., MacGregor I.R., Hunter N.R., and Bennett B. (1987). Plasminogen activator inhibitor from human endothelial cells. Purification and partial characterization.Eur. J. Biochem. 165, 595–600.

    Article  PubMed  CAS  Google Scholar 

  • Booth N.A., Robbie L.A., Croll A.M., and Bennett B. (1992). Lysis of platelet-rich thrombi: The role of PAI-1.Ann. NY Acad. Sci. 667, 70–80.

    Article  PubMed  CAS  Google Scholar 

  • Booth N.A., Simpson A.J., Croll A., Bennett B., and MacGregor I.R. (1988). Plasminogen activator inhibitor (PAI-1) in plasma and platelets.Br. J. Haematol. 70, 327–333.

    Article  PubMed  CAS  Google Scholar 

  • Bryans J., Charlton P.R., Collins M., Faint R., Latham C., Shaw I., and Trew S. (1996). Inhibition of plasminogen activator inhibitor 1 activity by two diketopiperazines, xr330 and xr334 produced by Streptomyces sp.J. Antibiot. 49, 1014–1021.

    Article  PubMed  CAS  Google Scholar 

  • Carmeliet P., Kieckens L., Schoonjans L., Ream B., Van Nuffelen A., Prendergast G., Cole M., Bronson R., Collen D., and Mulligan R.C. (1993). Plasminogen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterization.J. Clin. Invest. 92, 2746–2755.

    Article  PubMed  CAS  Google Scholar 

  • Carrell R. and Travis J. (1985). α1-Antitrypsin and the serpins: Variation and countervariation.TIBS20–24.

    Google Scholar 

  • Carrell R.W. and Boswell D.R. (1986). Serpins: The superfamily of plasma serine proteinase inhibitors. In Barrett, Salvesen (eds)Proteinase Inhibitors.Elsevier Science, pp. 403–420.

    Google Scholar 

  • Carrell R.W. and Stein P.E. (1996). The biostructural pathology of the serpins: Critical function of sheet opening mechanism.Biol. Chem. Hoppe Seyler 377, 1–17.

    Article  PubMed  CAS  Google Scholar 

  • Carrell R.W., Stein P.E., Fermi G., and Wardell M.R. (1994). Biological implications of a 3 A structure of dimeric antithrombin [see comments].Structure 2, 257–270.

    Article  PubMed  CAS  Google Scholar 

  • Charlton P., Faint R., Barnes C., Bent F., Folkes A., Templeton D., Mackie I., Machin S., and Bevan P. (1997). Xr5118, a novel modulator of plasminogen activator inhibitor 1 (pai 1), increases endogenous tpa activity in the rat.Fibrinolysis Proteolysis 11, 51–56.

    Article  CAS  Google Scholar 

  • Charlton P.A., Faint R.W., Bent F., Bryans J., Chicarelli-Robinson I., Mackie I., Machin S., and Bevan P. (1996). Evaluation of a low molecular weight modulator of human plasminogen activator inhibitor 1 activity.Thromb. Haemost. 75, 808–815.

    PubMed  CAS  Google Scholar 

  • Chikanishi T., Shinohara C., Kikuchi T., Endo A., and Hasumi K. (1999). Inhibition of plasminogen activator inhibitor-1 by 11-keto-9(E),12(E)-octadecadienoic acid, a novel fatty acid produced by Trichoderma sp.J. Antibiot. 52, 797–802.

    Article  PubMed  CAS  Google Scholar 

  • Chmielewska J., Carlsson T., Urden G., and Wiman B. (1987). On the relationship between different molecular forms of the fast inhibitor of tissue plasminogen activator.Fibrinolysis 1, 67–73.

    CAS  Google Scholar 

  • Chmielewska J., Ranby M., and Wiman B. (1988). Kinetics of the inhibition of plasminogen activators by the plasminogen-activator inhibitor. Evidence for “second-site” interactions.Biochem. J. 251, 327–332.

    PubMed  CAS  Google Scholar 

  • Coleman P.L., Barouski P.A., and Gelehrter T.D. (1982). The dexamethasone-induced inhibitor of fibrinolytic activity in hepatoma cells. A cellular product which specifically inhibits plasminogen activation.J. Biol. Chem. 257, 4260–4264.

    PubMed  CAS  Google Scholar 

  • Cooper S.T. and Church F.C. (1995). Reactive site mutants of recombinant protein C inhibitor.Biochim. Biophys. Acta 1246, 29–33.

    Article  PubMed  Google Scholar 

  • Cooper S.T., Whinna H.C., Jackson T.P., Boyd J.M., and Church F.C. (1995). Intermolecular interactions between protein C inhibitor and coagulation proteases.Biochemistry 34, 12991–12997.

    Article  PubMed  CAS  Google Scholar 

  • Dawson S.J., Wiman B., Hamsten A., Green F., Humphries S., and Henney A.M. (1993). The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells.J. Biol. Chem. 268, 10739–10745.

    PubMed  CAS  Google Scholar 

  • Debrock S. and Declerck P.J. (1997). Neutralization of plasminogen activator inhibitor-1 inhibitory properties: Identification of two different mechanisms.Biochim. Biophys. Acta 1337, 257–266.

    Article  PubMed  CAS  Google Scholar 

  • Debrock S. and Declerck P.J. (1998). Identification of a functional epitope in plasminogen activator inhibitor-1, not localized in the reactive center loop.Thromb. Haemost. 79, 597–601.

    PubMed  CAS  Google Scholar 

  • Declerck P.J., Alessi M.C., Verstreken M., Kruithof E.K., Juhan Vague I., and Collen D. (1988). Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay.Blood 71, 220–225.

    PubMed  CAS  Google Scholar 

  • Declerck P.J., De Mol M., Vaughan D.E., and Collen D. (1992). Identification of a conformationally distinct form of plasminogen activator inhibitor-1, acting as a noninhibitory substrate for tissue-type plasminogen activator.J. Biol. Chem. 267, 11693–11696.

    PubMed  CAS  Google Scholar 

  • Devy L., Blacher S., Grignet-Debrus C, Bajou K., Masson V., Gerard R.D., Gils A., Carmeliet G., Carmeliet P., Declerck P.J., Noel A., and Foidart J.M. (2002). The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent.FASEB J. 16, 147–154.

    Article  PubMed  CAS  Google Scholar 

  • Dickinson J.L., Bates E.J., Ferrante A., and Antalis T.M. (1995). Plasminogen activator inhibitor type 2 inhibits tumor necrosis factor alpha-induced apoptosis. Evidence for an alternate biological function.J. Biol. Chem. 270, 27894–27904.

    Article  PubMed  CAS  Google Scholar 

  • Dieval J., Nguyen G., Gross S., Delobel J., and Kruithof E.K. (1991). A lifelong bleeding disorder associated with a deficiency of plasminogen activator inhibitor type 1.Blood 77, 528–532.

    PubMed  CAS  Google Scholar 

  • Dougherty K.M., Pearson J.M., Yang A.Y., Westrick R.J., Baker M.S., and Ginsburg D. (1999a) The plasminogen activator inhibitor-2 gene is not required for normal murine development or survival.Proc. Natl. Acad. Sci. USA 96, 686–691.

    Article  PubMed  CAS  Google Scholar 

  • Dougherty K.M., Pearson J.M., Yang A.Y., Westrick R.J., Baker M.S., and Ginsburg D. (1999b) The plasminogen activator inhibitor-2 gene is not required for normal murine development or survival.Proc. Natl. Acad. Sci. USA 96, 686–691.

    Article  PubMed  CAS  Google Scholar 

  • Egelund R., Einholm A.P., Pedersen K.E., Nielsen R.W., Christensen A., Deinum J., and Andreasen P.A. (2001). A regulatory hydrophobic area in the flexible joint region of plasminogen activator inhibitor-1, defined with fluorescent activity-neutralizing ligands-Ligand-induced serpin polymerization.J. Biol. Chem. 276, 13077–13086.

    Article  PubMed  CAS  Google Scholar 

  • Ehnebom J., Bjorquist P., Andersson J.O., Johansson T., and Deinum J.R. (1997). Detergent tween 80 modifies the specific activity of pai 1.Fibrinolysis Proteolysis 11, 165–170.

    Article  CAS  Google Scholar 

  • Ehrlich A.J., Gebbink R.K., Keijer J., Linders M., Preissner K.T., and Pannekoek H. (1990). Alteration of serpin specificity by a protein cofactor. Vitronectin endows plasminogen activator inhibitor 1 with thrombin inhibitory properties.J. Biol. Chem. 265, 13029–13035.

    PubMed  CAS  Google Scholar 

  • Eitzman D.T., Fay W.P., Lawrence D.A., Francis Chmura A.M., Shore J.D., Olson S.T., and Ginsburg D. (1995). Peptide-mediated inactivation of recombinant and platelet plasminogen activator inhibitor-1 in vitro.J. Clin. Invest. 95, 2416–2420.

    Article  PubMed  CAS  Google Scholar 

  • Eitzman D.T., Krauss J.C., Shen T., Cui J., and Ginsburg (1996b). Lack of plasminogen activator inhibitor-1 effect in a transgenic mouse model of metastatic melanoma.Blood 87, 4718–4722.

    PubMed  CAS  Google Scholar 

  • Eitzman D.T., McCoy R.D., Zheng X., Fay W.P., Shen T., Ginsburg D., and Simon R.H. (1996a). Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene.J. Clin. Invest. 97, 232–237.

    Article  PubMed  CAS  Google Scholar 

  • Eitzman D.T., Westrick R.J., Nabel E.G., and Ginsburg D. (2000). Plasminogen activator inhibitor-1 and vitronectin promote vascular thrombosis in mice.Blood 95, 577–580.

    PubMed  CAS  Google Scholar 

  • Erickson L.A., Fici G.J., Lund J.E., Boyle T.P., Polites H.G., and Marotti K.R. (1990). Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor-1 gene.Nature 346, 74–76.

    Article  PubMed  CAS  Google Scholar 

  • Erickson L.A., Ginsberg M.H., and Loskutoff D.J. (1984). Detection and partial characterization of an inhibitor of plasminogen activator in human platelets.J. Clin. Invest. 74, 1465–1472.

    Article  PubMed  CAS  Google Scholar 

  • Eriksson P., Kallin B., van ‘t Hooft F.M., Bavenholm P., and Hamsten A. (1995). Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction.Proc. Natl. Acad. Sci. USA 92, 1851–1855.

    Article  PubMed  CAS  Google Scholar 

  • Espana F., Estelles A., Fernandez P.J., Gilabert J., Sanchez-Cuenca J., and Griffin J.H. (1993). Evidence for the regulation of urokinase and tissue type plasminogen activators by the serpin, protein C inhibitor, in semen and blood plasma.Thromb. Haemost. 70, 989–994.

    PubMed  CAS  Google Scholar 

  • Espana F., Gilabert J., Estelles A., Romeu A., Aznar J., and Cabo A. (1991). Functionally active protein C inhibitor/plasminogen activator inhibitor-3 (PCI/PAI-3) is secreted in seminal vesicles., occurs at high concentrations in human seminal plasma and complexes with prostate-specific antigen.Thromb. Res. 64, 309–320.

    Article  PubMed  CAS  Google Scholar 

  • Espana F., Vicente V., Tabernero D., Scharrer I., and Griffin J.H. (1990). Determination of plasma protein C inhibitor and of two activated protein C-inhibitor complexes in normals and in patients with intravascular coagulation and thrombotic disease.Thromb. Res. 59, 593–608.

    Article  PubMed  CAS  Google Scholar 

  • Fa M., Karolin J., Aleshkov S., Strandberg L., Johansson L.B., and Ny T. (1995). Time-resolved polarized fluorescence spectroscopy studies of plasminogen activator inhibitor type 1: Conformational changes of the reactive center upon interactions with target proteases, vitronectin and heparin.Biochemistry 34, 13833–13840.

    Article  PubMed  CAS  Google Scholar 

  • Farrehi P.M., Ozaki C.K., Carmeliet P., and Fay W.P. (1998). Regulation of arterial thrombolysis by plasminogen activator inhibitor-1 in mice.Circulation 97, 1002–1008.

    Article  PubMed  CAS  Google Scholar 

  • Fay W.P., Parker A.C., Condrey L.R., and Shapiro A.D. (1997). Human plasminogen activator inhibitor 1 (pai 1) deficiency: Characterization of a large kindred with a null mutation in the pai 1 gene.Blood 90, 204–208.

    PubMed  CAS  Google Scholar 

  • Folkes A., Roe M.B., Sohal S., Golec J., Faint R., Brooks T., and Charlton P. (2001). Synthesis and in vitro evaluation of a series of diketopiperazine inhibitors of plasminogen activator inhibitor-1.Bioorg. Med. Chem. Lett. 11, 2589–2592.

    Article  PubMed  CAS  Google Scholar 

  • Friederich P.W., Levi M.R., Biemond B.J., Charlton P., Templeton D., Vanzonneveld A.J., Bevan P., Pannekoek H., and Tencate J.W. (1997). Novel low molecular weight inhibitor of pai 1 (xr5118) promotes endogenous fibrinolysis and reduces postthrombolysis thrombus growth in rabbits.Circulation 96, 916–921.

    PubMed  CAS  Google Scholar 

  • Gardsvoll H., van-Zonneveld A.J., Holm A., Eldering E., van-Meijer M., Dano K., and Pannekoek H. (1998). Selection of peptides that bind to plasminogen activator inhibitor 1 (PAI-1) using random peptide phage-display libraries.FEBS Lett. 431, 170–174.

    Article  PubMed  CAS  Google Scholar 

  • Geiger M., Huber K., Wojta J., Stingl L., Espana F., Griffin J.H., and Binder B.R. (1989). Complex formation between urokinase and plasma protein C inhibitor in vitro and in vivo.Blood 74, 722–728.

    PubMed  CAS  Google Scholar 

  • Gils A. and Declerck P.J. (1997). Proteinase specificity and functional diversity in point mutants of plasminogen activator inhibitor 1.J. Biol. Chem. 272, 12662–12666.

    Article  PubMed  CAS  Google Scholar 

  • Gils A. and Declerck P.J. (1998a). Modulation of plasminogen activator inhibitor 1 by Triton X-100-Identification of two consecutive conformational transitions.Thromb. Haemost. 80, 286–291.

    PubMed  CAS  Google Scholar 

  • Gils A. and Declerck P.J. (1998b). Structure-function relationship in serpins: Current concepts and controversies.Thromb. Haemost. 80, 531–541.

    PubMed  CAS  Google Scholar 

  • Gils A., Knockaert I., and Declerck P.J. (1996). Substrate behavior of plasminogen activator inhibitor-1 is not associated with a lack of insertion of the reactive site loop.Biochemistry 35, 7474–7481.

    Article  PubMed  CAS  Google Scholar 

  • Ginsburg D., Zeheb R., Yang A.Y., Rafferty U.M., Andreasen P.A., Nielsen L., Dano K., Lebo R.V., and Gelehrter T.D. (1986). cDNA cloning of human plasminogen activator-inhibitor from endothelial cells.J. Clin. Invest. 78, 1673–1680.

    Article  PubMed  CAS  Google Scholar 

  • Glauser M.P., Zanetti G., Baumgartner J.D., and Cohen J. (1991). Septic shock: Pathogenesis.Lancet 338, 732–736.

    Article  PubMed  CAS  Google Scholar 

  • Hamsten A., de Faire U., Walldius G., Dahlen G., Szamosi A., Landou C., Blomback M., and Wiman B. (1987). Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction.Lancet 2, 3–9.

    Article  PubMed  CAS  Google Scholar 

  • Hamsten A., Wiman B., de Faire U., and Blomback M. (1985). Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction.N. Engl. J. Med. 313, 1557–1563.

    Article  PubMed  CAS  Google Scholar 

  • Hansen M., Busse M.N., and Andreasen P.A. (2001). Importance of the amino-acid composition of the shutter region of plasminogen activator inhibitor-1 for its transitions to latent and substrate forms.Eur. J. Biochem. 268, 6274–6283.

    Article  PubMed  CAS  Google Scholar 

  • Harrop S.J., Jankova L., Coles M., Jardine D., Whittaker J.S., Gould A.R., Meister A., King G.C., Mabbutt B.C., and Curmi P.M. (1999). The crystal structure of plasminogen activator inhibitor 2 at 2.0 A resolution: implications for serpin function.Struct. Fold. Des. 7, 43–54.

    Article  CAS  Google Scholar 

  • Heeb M.J., Espana F., Geiger M., Collen D., Stump D.C., and Griffin J.H. (1987). Immunological identity of heparin-dependent plasma and urinary protein C inhibitor and plasminogen activator inhibitor-3.J. Biol. Chem. 262, 15813–15816.

    PubMed  CAS  Google Scholar 

  • Hekman C.M. and Loskutoff D.J. (1985). Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants.J. Biol. Chem. 260, 11581–11587.

    PubMed  CAS  Google Scholar 

  • Hekman C.M. and Loskutoff D.J. (1988). Bovine plasminogen activator inhibitor 1: Specificity determinations and comparison of the active, latent, and guanidine-activated forms.Biochemistry 27, 2911–2918.

    Article  PubMed  CAS  Google Scholar 

  • Henry M., Tregouet D.A., Alessi M.C., Aillaud M.F., Visvikis S., Siest G., Tiret L., and Juhan-Vague I. (1998). Metabolic determinants are much more important than genetic polymorphisms in determining the PAI-1 activity and antigen plasma concentrations: A family study with part of the Stanislas Cohort.Arterioscler. Thromb. Vasc. Biol. 18, 84–91.

    Article  PubMed  CAS  Google Scholar 

  • Hermans J.M., Jones R., and Stone S.R. (1994). Rapid inhibition of the sperm protease acrosin by protein C inhibitor.Biochemistry 33, 5440–5444.

    Article  PubMed  CAS  Google Scholar 

  • Hermans J.M. and Stone S.R. (1993). Interaction of activated protein C with serpins.Biochem J. 295, 45.

    Google Scholar 

  • Hoess R.H., Mack A.J., Walton H., and Reilly T.M. (1994). Identification of a structural epitope by using a peptide library displayed on filamentous bacteriophage.J. Immunol. 153, 724–729.

    PubMed  CAS  Google Scholar 

  • Hofmann K.J., Mayer E.J., Schultz L.D., Socher S.H., and Reilly C.F. (1992). Purification and characterisation of recombinant rabbit plasminogen activator inhibitor-1 expressed in Saccharomyces cerevisiae.Fibrinolysis 6, 263–272.

    CAS  Google Scholar 

  • Huber K. (2001). Plasminogen activator inhibitor type-1 (part two): Role for failure of thrombolytic therapy. PAI-1 resistance as a potential benefit for new fibrinolytic agents.J. Thromb. Thrombol. 11, 195–202.

    Article  CAS  Google Scholar 

  • Huber R. and Carrell R.W. (1989). Implications of the three-dimensional structure of alpha 1-antitrypsin for structure and function of serpins.Biochemistry 28, 8951–8966.

    Article  PubMed  CAS  Google Scholar 

  • Huntington J.A., Read R.J., and Carrell R.W. (2000). Structure of a serpin-protease complex shows inhibition by deformation.Nature 407, 923–926.

    Article  PubMed  CAS  Google Scholar 

  • Hynes R.O. (1992). Integrins: Versatility, modulation, and signaling in cell adhesion.Cell 69, 11–25.

    Article  PubMed  CAS  Google Scholar 

  • Janicke F., Schmitt M., Pache L., Ulm K., Harbeck N., Hofler H., and Graeff H. (1993). Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer.Breast Cancer Res. Treat. 24, 195–208.

    Article  PubMed  CAS  Google Scholar 

  • Jankova L., Harrop S.J., Saunders D.N., Andrews J.L., Bertram K.C., Gould A.R., Baker M.S., and Curmi P.M. (2001). Crystal structure of the complex of plasminogen activator inhibitor 2 with a peptide mimicking the reactive center loop.J. Biol. Chem. 276, 43374–43382.

    Article  PubMed  CAS  Google Scholar 

  • Jensen PH., Schuler E., Woodrow G., Richardson M., Goss N., Hojrup P., Petersen T.E., and Rasmussen L.K. (1994). A unique interhelical insertion in plasminogen activator inhibitor-2 contains three glutamines, Gln83, Gln84, Gln86, essential for transglutaminase-mediated cross-linking.J. Biol. Chem. 269, 15394–15398.

    PubMed  CAS  Google Scholar 

  • Jin L., Abrahams J.P., Skinner R., Petitou M., Pike R.N., and Carrell R.W. (1997). The anticoagulant activation of antithrombin by heparin.Proc. Natl. Acad. Sci. USA 94, 14683–14688.

    Article  PubMed  CAS  Google Scholar 

  • Juhan Vague I., Moerman B., De Cock F., Aillaud M.F., and Collen D. (1984). Plasma levels of a specific inhibitor of tissue-type plasminogen activator (and urokinase) in normal and pathological conditions.Thromb. Res. 33, 523–530.

    Article  PubMed  CAS  Google Scholar 

  • Juhan Vague I., Pyke S.D.M., Alessi M.C., Jespersen J., Haverkate F., and Thompson S.G. (1996). Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris.Circulation 94, 2057–2063.

    Article  PubMed  CAS  Google Scholar 

  • Keijer J., Linders M., van Zonneveld A.J., Ehrlich H.J., de Boer J.P., and Pannekoek H. (1991b). The interaction of plasminogen activator inhibitor 1 with plasminogen activators (tissue-type and urokinase-type) and fibrin: Localization of interaction sites and physiologic relevance.Blood 78, 401–409.

    PubMed  CAS  Google Scholar 

  • Keijer J., Linders M., Wegman J.J., Ehrlich H.J., Mertens K., and Pannekoek H. (1991a). On the target specificity of plasminogen activator inhibitor 1: The role of heparin, vitronectin, and the reactive site.Blood 78, 1254–1261.

    PubMed  CAS  Google Scholar 

  • Kimura S. and Aoki N. (1986). Cross-linking site in fibrinogen for alpha 2-plasmin inhibitor.J. Biol. Chem. 261, 15591–15595

    PubMed  CAS  Google Scholar 

  • Kjoller L., Martensen P.M., Sottrupjensen L., Justesen J., Rodenburg K.W., and Andreasen P.A. (1996). Conformational changes of the reactive centre loop and beta strand 5a accompany temperature dependent inhibitor substrate transition of plasminogen activator inhibitor 1.Eur. J. Biochem. 241, 38–46.

    Article  PubMed  CAS  Google Scholar 

  • Kobylanska A., Pluskota E., Pawlowska Z.., Okruszek A., Cierniewski C.S., and Stec W.J. (1999). The cytotoxicity of anti-PAI-I oligonucleotides and their conjugates.Nucleosides Nucleotides 18, 1709–1710.

    Article  PubMed  CAS  Google Scholar 

  • Kornelisse R.F., Hazelzet J.A., Savelkoul H.F., Hop W.C., Suur M.H., Borsboom A.N., Risseeuw Appel I.M., van der Voort E., and de Groot R. (1996). The relationship between plasminogen activator inhibitor-1 and proinflammatory and counterinflammatory mediators in children with meningococcal septic shock.J. Infect. Dis. 173, 1148–1156.

    Article  PubMed  CAS  Google Scholar 

  • Kruithof E.K., Baker M.S., and Bunn C.L. (1995). Biological and clinical aspects of plasminogen activator inhibitor type 2.Blood 86, 4007–4024.

    PubMed  CAS  Google Scholar 

  • Kruithof E.K., Nicolosa G., and Bachmann F. (1987). Plasminogen activator inhibitor 1: Development of a radioimmunoassay and observations on its plasma concentration during venous occlusion and after platelet aggregation.Blood 70, 1645–1653.

    PubMed  CAS  Google Scholar 

  • Kruithof E.K., Tran Thang C., Ransijn A., and Bachmann F. (1984). Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma.Blood 64, 907–913.

    PubMed  CAS  Google Scholar 

  • Kruithof E.K., Vassalli J.D., Schleuning W.D., Mattaliano R.J., and Bachmann F. (1986). Purification and characterization of a plasminogen activator inhibitor from the histiocytic lymphoma cell line U-937.J. Biol.Chem. 261, 11207–11213.

    PubMed  CAS  Google Scholar 

  • Kuhn W., Pache L., Schmalfeldt B., Dettmar P., Schmitt M., Janicke F., and Graeff H. (1994). Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy.Gynecol. Oncol. 55, 401–409.

    Article  PubMed  CAS  Google Scholar 

  • Kvassman J.O., Lawrence D.A., and Shore J.D. (1995). The acid stabilization of plasminogen activator inhibitor-1 depends on protonation of a single group that affects loop insertion into beta-sheet A.J. Biol. Chem. 270,27942–27947.

    Article  PubMed  CAS  Google Scholar 

  • Lambers J.W., Cammenga M., Konig B.W., Mertens K., Pannekoek H., and van Mourik J.A. (1987). Activation of human endothelial cell-type plasminogen activator inhibitor (PAI-1) by negatively charged phospholipids.J. Biol. Chem. 262, 17492–17496.

    PubMed  CAS  Google Scholar 

  • Laskowski M., Jr., Kato I. (1980). Protein inhibitors of proteinases.Annu. Rev. Biochem. 49, 593–626.

    Article  PubMed  CAS  Google Scholar 

  • Laurell M., Christensson A., Abrahamsson P.A., Stenflo J., and Lilja H. (1992). Protein C inhibitor in human body fluids. Seminal plasma is rich in inhibitor antigen deriving from cells throughout the male reproductive system.J. Clin. Invest. 89, 1094–1101.

    Article  PubMed  CAS  Google Scholar 

  • Lawrence D., Strandberg L., Grundstrom T., and Ny T. (1989). Purification of active human plasminogen activator inhibitor 1 from Escherichia coli. Comparison with natural and recombinant forms purified from eucaryotic cells.Eur. J. Biochem. 186, 523–533.

    Article  PubMed  CAS  Google Scholar 

  • Lawrence D.A., Strandberg L., Ericson J., and Ny T. (1990). Structure-function studies of the SERPIN plasminogen activator inhibitor type 1. Analysis of chimeric strained loop mutants.J. Biol. Chem. 265,20293–20301.

    PubMed  CAS  Google Scholar 

  • Lecander I., Astedt B. (1986). Isolation of a new specific plasminogen activator inhibitor from pregnancy plasma.Br. J. Haematol. 62, 221–228.

    Article  PubMed  CAS  Google Scholar 

  • Lee M.H., Vosburgh E., Anderson K., and McDonagh J. (1993). Deficiency of plasma plasminogen activator inhibitor 1 results in hyperfibrinolytic bleeding.Blood 81, 2357–2362.

    PubMed  CAS  Google Scholar 

  • Levi M., Biemond B.J., van Zonneveld A.J., ten Cate J.W., and Pannekoek H. (1992). Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis [see comments].Circulation 85, 305–312.

    Article  PubMed  CAS  Google Scholar 

  • Levi M., ten-Cate H., van-der-Poll T., and van-Deventer S.J. (1993). Pathogenesis of disseminated intravascular coagulation in sepsis.JAMA 270, 975–979.

    Article  PubMed  CAS  Google Scholar 

  • Loskutoff D.J., Edgington T.S. (1981). An inhibitor of plasminogen activator in rabbit endothelial cells.J. Biol.Chem. 256, 4142–4145.

    PubMed  CAS  Google Scholar 

  • Loskutoff D.J., van Mourik J.A., Erickson L.A., and Lawrence D. (1983). Detection of an unusually stable fibrinolytic inhibitor produced by bovine endothelial cells.Proc. Natl. Acad. Sci. USA 80, 2956–2960.

    Article  PubMed  CAS  Google Scholar 

  • Madison E.L., Goldsmith E.J., Gerard R.D., Gething M.J., and Sambrook J.F. (1989). Serpin-resistant mutants of human tissue-type plasminogen activator.Nature 339, 721–724.

    Article  PubMed  CAS  Google Scholar 

  • Madison E.L., Goldsmith E.J., Gething M.J., Sambrook J.F., and Gerard R.D. (1990). Restoration of serine protease-inhibitor interaction by protein engineering.J. Biol. Chem. 265, 21423–21426.

    PubMed  CAS  Google Scholar 

  • Margaglione M., Grandone E., Vecchione G., Cappucci G., Giuliani N., Colaizzo D., Celentano E., Panico S.,and Diminno G.R. (1997). Plasminogen activator inhibitor 1 (pai 1) antigen plasma levels in subjects attending a metabolic ward: Relation to polymorphisms of pai 1 and angiotensin converting enzyme (ace) genes.Arterioscler. Thromb. Vasc. Biol. 17, 2082–2087.

    Article  PubMed  CAS  Google Scholar 

  • Meijers J.C., Kanters D.H., Vlooswijk R.A., van-Erp H.E., Hessing M., and Bouma B.N. (1988). Inactivation of human plasma kallikrein and factor XIa by protein C inhibitor.Biochemistry 27, 4231–4237.

    Article  PubMed  CAS  Google Scholar 

  • Mesters R.M., Florke N., Ostermann H., and Kienast J. (1996). Increase of plasminogen activator inhibitor levels predicts outcome of leukocytopenic patients with sepsis.Thromb. Haemost. 75, 902–907.

    PubMed  CAS  Google Scholar 

  • Mikus P., Ny T. (1996). Intracellular polymerization of the serpin plasminogen activator inhibitor type 2.J. Biol.Chem. 271, 10048–10053.

    Article  PubMed  CAS  Google Scholar 

  • Mikus P., Urano T., Liljestrom P., and Ny T. (1993). Plasminogen-activator inhibitor type 2 (PAI-2) is a spontaneously polymerising SERPIN. Biochemical characterisation of the recombinant intracellular and extracellular forms.Eur. J. Biochem. 218, 1071–1082.

    Article  PubMed  CAS  Google Scholar 

  • Mimuro J., Sawdey M., Hattori M., and Luskutoff D.J. (1989). cDNA for bovine type 1 plasminogen activator inhibitor (PAI-1).Nucleic Acids Res. 17, 8872–8872.

    Article  PubMed  CAS  Google Scholar 

  • Minamikawa K., Wada H., Wakita Y., Ohiwa M., Tanigawa M., Deguchi K., Hiraoka N., Huzioka H., Nishioka J., and Hayashi T., et al. (1994). Increased activated protein C-protein C inhibitor complex levels in patients with pulmonary embolism.Thromb. Haemost. 71, 192–194.

    PubMed  CAS  Google Scholar 

  • Mosnier L.O., Elisen M.G., Bouma B.N., and Meijers J.C. (2001). Protein C inhibitor regulates the thrombin-thrombomodulin complex in the up- and down regulation of TAFI activation.Thromb. Haemost. 86, 1057–1064.

    PubMed  CAS  Google Scholar 

  • Mottonen J., Strand A., Symersky J., Sweet R.M., Danley D.E., Geoghegan K.F., Gerard R.D., and Goldsmith E.J. (1992). Structural basis of latency in plasminogen activator inhibitor-1.Nature 355, 270–273.

    Article  PubMed  CAS  Google Scholar 

  • Muehlenweg B., Guthaus E., de P.N., Schmitt M., Schmiedeberg N., Kotzsch M., Creutzburg S., Kramer M.D., Kessler H., Wilhelm O.G., and Magdolen V. (2000). Epitope mapping of monoclonal antibodies directed to PAI-1 using PAI-1/PAI-2 chimera and PAI-1 -derived synthetic peptides.Thromb. Res. 98, 73–81.

    Article  PubMed  CAS  Google Scholar 

  • Munch M., Heegaard C.W., and Andreasen P.A. (1993). Interconversions between active, inert and substrate forms of denatured/refolded type-1 plasminogen activator inhibitor.Biochim. Biophys. Acta 1202, 29–37.

    Article  PubMed  CAS  Google Scholar 

  • Nar H., Bauer M., Stassen J.M., Lang D., Gils A., and Declerck P.J. (2000). Plasminogen activator inhibitor 1. Structure of the native serpin, comparison to its other conformers and implications for serpin inactivation.J. Mol. Biol. 297, 683–695

    Article  PubMed  CAS  Google Scholar 

  • Neese L.L., Wolfe C.A., and Church F.C. (1998). Contribution of basic residues of the d and h helices in heparin binding to protein c inhibitor.Arch. Biochem. Biophy. 355, 101–108.

    Article  CAS  Google Scholar 

  • Nekarda H., Siewert J.R., Schmitt M., and Ulm K. (1994). Tumour-associated proteolytic factors uPA and PAI-1 and survival in totally resected gastric cancer.Lancet 343, 117.

    Article  PubMed  CAS  Google Scholar 

  • Ngo T.H., Declerck P.J. (1998). Suppression of plasminogen activator inhibitor 1 (PAI-1) activity levels in rats by monoclonal antibodies.Fibrinolysis Proteolysis 12, 335–339.

    Article  CAS  Google Scholar 

  • Ngo T.H., Hoylaerts M.F., Knockaert I., Brouwers E., and Declerck P.J. (2001). Identification of a target site in plasminogen activator inhibitor-1 that allows neutralization of its inhibitory properties concomitant with an allosteric up-regulation of its antiadhesive properties.J. Biol. Chem. 276, 26243–26248.

    Article  PubMed  CAS  Google Scholar 

  • Ny T., Sawdey M., Lawrence D., Millan J.L., and Loskutoff D.J. (1986). Cloning and sequence of a cDNA coding for the human beta- migrating endothelial-cell-type plasminogen activator inhibitor.Proc. Natl. Acad. Sci. USA 83, 6776–6780.

    Article  PubMed  CAS  Google Scholar 

  • Olson S.T., Bock P.E., Kvassman J., Shore J.D., Lawrence D.A., Ginsburg D., and Bjork I. (1995). Role of the catalytic serine in the interactions of serine proteinases with protein inhibitors of the serpin family. Contribution of a covalent interaction to the binding energy of serpin-proteinase complexes.J. Biol. Chem. 270, 30007–30017.

    Article  PubMed  CAS  Google Scholar 

  • Pannekoek H., Veerman H., Lambers H., Diergaarde P., Verweij C.L., van Zonneveld A.J., and van Mourik J.A. (1986). Endothelial plasminogen activator inhibitor (PAI): A new member of the Serpin gene family.EMBO J. 5, 2539–2544.

    PubMed  CAS  Google Scholar 

  • Paoni N.F., Keyt B.A., Refino C.J., Chow A.M., Nguyen H.V., Berleau L.T., Badillo J., Pena L.C., Brady K., and Wurm F.M.,et al.(1993). A slow clearing, fibrin-specific, PAI-1 resistant variant of t-PA (T103N, KHRR 296-299 AAAA).Thromb. Haemost. 70, 307–312.

    PubMed  CAS  Google Scholar 

  • Pedersen H., Grondahl Hansen J., Francis D., Osterlind K., Hansen H.H., Dano K., and Brunner N. (1994). Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma.Cancer Res. 54, 120–123.

    PubMed  CAS  Google Scholar 

  • Perrie A.M., MacGregor I.R., and Booth N.A. (1993). Definition of epitopes within plasminogen activator inhibitor type-1 (PAI-1) using multiple peptide synthesis.Fibrinolysis 7, 257–263.

    CAS  Google Scholar 

  • Phillips J.E., Cooper S.T., Potter E.E., and Church EC. (1994). Mutagenesis of recombinant protein C inhibitor reactive site residues alters target proteinase specificity.J. Biol. Chem. 269, 16696–16700.

    PubMed  CAS  Google Scholar 

  • Pratt C.W., Church F.C. (1992). Heparin binding to protein C inhibitor.J. Biol. Chem. 267, 8789–8794.

    PubMed  CAS  Google Scholar 

  • Prendergast G.C., Diamond L.E., Dahl D., and Cole M.D. (1990). The c-myc-regulated gene mrl encodes plasminogen activator inhibitor 1.Mol. Cell. Biol. 10, 1265–1269.

    PubMed  CAS  Google Scholar 

  • Radtke K.P., Fernandez J.A., Greengard J.S., Tang W.W., Wilson C.B., Loskutoff D.J., Scharrer I., and Griffin J.H. (1994). Protein C inhibitor is expressed in tubular cells of human kidney.J. Clin. Invest. 94, 2117–2124.

    Article  PubMed  CAS  Google Scholar 

  • Radtke K.P., Fernandez J.A., Villoutreix B.O., Greengard J.S., and Griffin J.H. (1995). Characterization of a cDNA for rhesus monkey protein C inhibitor-evidence for N-terminal involvement in heparin stimulation.Thromb. Haemost. 74, 1079–1087.

    CAS  Google Scholar 

  • Rezaie A.R., Cooper S.T., Church EC, and Esmon C.T. (1995). Protein C inhibitor is a potent inhibitor of the thrombin-thrombomodulin complex.J. Biol. Chem. 270, 25336–25339.

    Article  PubMed  CAS  Google Scholar 

  • Ridker P.M., Gaboury C.L., Conlin P.R., Seely E.W., Williams G.H., and Vaughan D.E. (1993). Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function.Circulation 87, 1969–1973.

    Article  PubMed  CAS  Google Scholar 

  • Ridker P.M., Hennekens C.H., Lindpaintner K., Stampfer M.J., and Miletich J.P. (1997). Arterial and venous thrombosis is not associated with the 4g/5g polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of us men.Circulation 95, 59–62.

    Article  PubMed  CAS  Google Scholar 

  • Ritchie H., Booth N.A. (1998). Secretion of plasminogen activator inhibitor 2 by human peripheral blood monocytes occurs via an endoplasmic reticulum-golgi-independent pathway.Exp. Cell Res. 242, 439–450.

    Article  PubMed  CAS  Google Scholar 

  • Ritchie H., Lawrie L.C., Crombie P.W., Mosesson M.W., and Booth N.A. (2000). Cross-linking of plasminogen activator inhibitor 2 and alpha(2)-antiplasmin to fibrin(ogen).J. Biol. Chem. 275, 24915–24920.

    Article  PubMed  CAS  Google Scholar 

  • Ritchie H., Robbie L.A., Kinghorn S., Exley R., and Booth N.A. (1999). Monocyte plasminogen activator inhibitor 2 (PAI-2) inhibits u-PA-mediated fibrin clot lysis and is cross-linked to fibrin.Thromb. Haemost. 81, 96–103.

    PubMed  CAS  Google Scholar 

  • Rodenburg K.W., Kjoller L., Petersen H.H., and Andreasen P.A. (1998). Binding of urokinase-type plasminogen activator plasminogen activator inhibitor-1 complex to the endocytosis receptors alpha(2)-macroglobulin receptor low-density lipoprotein receptor- related protein and very-low-density lipoprotein receptor involves basic residues in the inhibitor.Biochem. J. 329(Part 1); 55–63.

    PubMed  CAS  Google Scholar 

  • Sancho E., Tonge D.W., Hockney R.C., and Booth N.A. (1994). Purification and characterization of active and stable recombinant plasminogen-activator inhibitor accumulated at high levels in Escherichia coli. Eur. J. Biochem. 224, 125–134.

    Article  PubMed  CAS  Google Scholar 

  • Saunders D.N., Buttigieg K.M., Gould A., McPhun V., and Baker M.S. (1998). Immunological detection of conformational neoepitopes associated with the serpin activity of plasminogen activator inhibitor type-2. J. Biol. Chem. 273, 10965–10971.

    Article  PubMed  CAS  Google Scholar 

  • Schleef R.R., Higgins D.L., Pillemer E., and Levitt L.J. (1989). Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor. J. Clin. Invest. 83, 1747–1752.

    Article  PubMed  CAS  Google Scholar 

  • Schleuning W.D., Medcalf R.L., Hession C., Rothenbuhler R., Shaw A., and Kruithof E.K. (1987). Plasminogen activator inhibitor 2: Regulation of gene transcription during phorbol ester-mediated differentiation of U-937 human histiocytic lymphoma cells. Mol. Cell. Biol. 7, 4564–4567.

    PubMed  CAS  Google Scholar 

  • Schneider S.S., Schick C., Fish K.E., Miller E., Pena J.C., Treter S.D., Hui S.M., and Silverman G.A. (1995). A serine proteinase inhibitor locus at 18q21.3 contains a tandem duplication of the human squamous cell carcinoma antigen gene. Proc. Natl. Acad. Sci. USA 92, 3147–3151.

    Article  PubMed  CAS  Google Scholar 

  • Schreuder H.A., de Boer B., Dijkema R., Mulders J., Theunissen H.J., Grootenhuis P.D., and Hol W.G. (1994). The intact and cleaved human antithrombin III complex as a model for serpin-proteinase interactions. Nat. Struct. Biol. 1, 48–54.

    Article  PubMed  CAS  Google Scholar 

  • Sharp A.M., Stein P.E., Pannu N.S., Carrell R.W., Berkenpas M.B., Ginsburg D., Lawrence D.A., and Read R.J. (1999). The active conformation of plasminogen activator inhibitor 1, a target for drugs to control fibrinolysis and cell adhesion.Struc. Fold. Des. 7, 111–118.

    Article  CAS  Google Scholar 

  • Sherman P.M., Lawrence D.A., Verhamme I.M., Paielli D., Shore J.D., Ginsburg D. (1995). Identification of tissue-type plasminogen activator-specific plasminogen activator inhibitor-1 mutants. Evidence that second sites of interaction contribute to target specificity.J. Biol. Chem. 270, 9301–9306.

    Article  PubMed  CAS  Google Scholar 

  • Sherman P.M., Lawrence D.A., Yang A.Y., Vandenberg E.T., Paielli D., Olson S.T., Shore J.D., and Ginsburg D. (1992). Saturation mutagenesis of the plasminogen activator inhibitor-1 reactive center.J. Biol. Chem. 267, 7588–7595.

    PubMed  CAS  Google Scholar 

  • Stec W.J., Cierniewski C.S., Okruszek A., Kobylanska A., Pawlowska Z., Koziolkiewicz M., Pluskota E., Maciaszek A., Rebowska B., and Stasiak M. (1997). Stereodependent inhibition of plasminogen activator inhibitor type 1 by phosphorothioate oligonucleotides: Proof of sequence specificity in cell culture and in vivo rat experiments.Antisense Nucleic Acid Drug Dev. 7, 567–573.

    Article  PubMed  CAS  Google Scholar 

  • Stefansson S., Lawrence D.A. (1996). The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta3 binding to vitronectin [see comments].Nature 383, 441–443.

    Article  PubMed  CAS  Google Scholar 

  • Stein P.E., Carrell R.W. (1995). What do dysfunctional serpins tell us about molecular mobility and disease?Nat. Struct. Biol. 2, 96–113.

    Article  PubMed  CAS  Google Scholar 

  • Stewart R.J., Fredenburgh J.C., Leslie B.A., Keyt B.A., Rischke J.A., and Weitz J.I. (2000). Identification of the mechanism responsible for the increased fibrin specificity of TNK-tissue plasminogen activator relative to tissue plasminogen activator.J. Biol. Chem. 275, 10112–10120.

    Article  PubMed  CAS  Google Scholar 

  • Stoop A.A., Jespers L., Lasters I., Eldering E., and Pannekoek H. (2000). High-density mutagenesis by combined DMA shuffling and phage display to assign essential amino acid residues in protein-protein interactions: Application to study structure-function of plasminogen activation inhibitor 1 (PAI-I).J. Mol. Biol. 301, 1135–1147.

    Article  PubMed  CAS  Google Scholar 

  • Stump D.C., Thienpont M., and Collen D. (1986). Purification and characterization of a novel inhibitor of urokinase from human urine. Quantitation and preliminary characterization in plasma.J. Biol. Chem. 261, 12759–12766.

    PubMed  CAS  Google Scholar 

  • Suzuki K. (1993). Protein C inhibitor.Methods Enzymol. 222, 385–399.

    Article  PubMed  CAS  Google Scholar 

  • Suzuki K., Deyashiki Y., Nishioka J., Kurachi K., Akira M., Yamamoto S., and Hashimoto S. (1987). Characterization of a cDNA for human protein C inhibitor. A new member of the plasma serine protease inhibitor superfamily.J. Biol. Chem. 262, 611–616.

    PubMed  CAS  Google Scholar 

  • Suzuki K., Nishioka J., Hashimoto S., Kamiya T., and Saito H. (1983). Normal titer of functional and immunore-active protein-C inhibitor in plasma of patients with congenital combined deficiency of factor V and factor VIII.Blood 62, 1266–1270.

    PubMed  CAS  Google Scholar 

  • Tucker H.M., Gerard R.D. (1996). Sequence requirements in the reactive-center loop of plasminogen activator inhibitor-1 for recognition of plasminogen activators.Eur. J. Biochem. 237, 180–187.

    Article  PubMed  CAS  Google Scholar 

  • Uchiyama T., Kurabayashi M., Ohyama Y., Utsugi T., Akuzawa N., Sato M., Tomono S., Kawazu S., and Nagai R. (2000). Hypoxia induces transcription of the plasminogen activator inhibitor-1 gene through genistein-sensitive tyrosine kinase pathways in vascular endothelial cells.Arterioscler. Thromb. Vasc. Biol. 20, 1155–1161.

    Article  PubMed  CAS  Google Scholar 

  • Urano T., Strandberg L., Johansson L.B., and Ny T. (1992). A substrate-like form of plasminogen-activator-inhibitor type 1. Conversions between different forms by sodium dodecyl sulphate.Eur. J. Biochem. 209, 985–992.

    Article  PubMed  CAS  Google Scholar 

  • van Mourik J.A., Lawrence D.A., and Loskutoff D.J. (1984). Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells.J. Biol. Chem. 259, 14914–14921.

    PubMed  Google Scholar 

  • Vaughan D.E., Lazos S.A., and Tong K. (1995). Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis.J. Clin. Invest. 95, 995–1001.

    Article  PubMed  CAS  Google Scholar 

  • Verheijen J.H., Chang G.T., and Kluft C. (1984). Evidence for the occurrence of a fast-acting inhibitor for tissue-type plasminogen activator in human plasma.Thromb. Haemost. 51, 392–395.

    PubMed  CAS  Google Scholar 

  • Wagner O.F., Vetterlein M., and Binder B.R. (1986). Purification of an active plasminogen activator inhibitor immunologically related to the endothelial type plasminogen activator inhibitor from the conditioned media of a human melanoma cell line [published erratum appears in J. Biol. Chem. 1988 Jan 25; 263(3), 1593].J. Biol. Chem. 261, 14474–14481.

    PubMed  CAS  Google Scholar 

  • Wakita T., Hayashi T., Yuasa H., Nishioka J., Kawamura J., and Suzuki K. (1998). Molecular cloning, tissue distribution and androgen regulation of rat protein C inhibitor.FEBS Lett. 429, 263–268.

    Article  PubMed  CAS  Google Scholar 

  • Webb A.C., Collins K.L., Snyder S.E., Alexander S.J., Rosenwasser L.J., Eddy R.L., Shows T.B., and Auron P.E. (1987). Human monocyte Arg-Serpin cDNA. Sequence, chromosomal assignment, and homology to plasminogen activator-inhibitor.J. Exp. Med. 166, 77–94.

    Article  PubMed  CAS  Google Scholar 

  • Wind T., Jensen M.A., and Andreasen P.A. (2001). Epitope mapping for four monoclonal antibodies against human plasminogen activator inhibitor type-1-Implications for antibody-mediated PAI-1-neutralization and vitronectin-binding.Eur. J. Biochem. 268, 1095–1106.

    Article  PubMed  CAS  Google Scholar 

  • Wohlwend A., Belin D., and Vassalli J.D. (1987). Plasminogen activator-specific inhibitors produced by human monocytes/macrophages.J. Exp. Med. 165, 320–339.

    Article  PubMed  CAS  Google Scholar 

  • Xue Y., Björquist P., Inghardt T., Linschoten M., Musil D., Sjölin L., and Deinum J. (1998). Interfering with the inhibitory mechanism of serpins: Crystal structure of a complex formed between cleaved plasminogen activator inhibitor type 1 and a reactive-centre loop peptide.Structure 6, 627–636.

    Article  PubMed  CAS  Google Scholar 

  • York J.D., Li P., and Gardell S.J. (1991). Combinatorial mutagenesis of the reactive site region in plasminogen activator inhibitor I.J. Biol. Chem. 266, 8495–8500.

    PubMed  CAS  Google Scholar 

  • Yuasa H., Tanaka H., Hayashi T., Wakita T., Nakamura H., Nishioka J., Kawarada Y., and Suzuki K. (2000). Bovine protein C inhibitor has a unique reactive site and can transiently inhibit plasmin.Thromb. Haemost. 83, 262–267.

    PubMed  CAS  Google Scholar 

  • Zechmeister-Machhart M., Hufnagl P., Uhrin P., Korschineck I., Binder B.R., and Geiger M. (1997). Molecular cloning and sequence analysis of the mouse protein C inhibitor gene.Gene 186, 61–66.

    Article  PubMed  CAS  Google Scholar 

  • Zeheb R., Gelehrter T.D. (1988). Cloning and sequencing of cDNA for the rat plasminogen activator inhibitor-1.Gene 73, 459–468.

    Article  PubMed  CAS  Google Scholar 

  • Zhou A., Faint R., Charlton P., Dafforn T.R., Carrell R.W., and Lomas D.A. (2001). Polymerization of plasminogen activator inhibitor-1.J. Biol. Chem. 276, 9115–9122.

    Article  PubMed  CAS  Google Scholar 

  • Zhu Y.H., Carmeliet P., and Fay W.P. (1999). Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistance.Circulation 99, 3050–3055.

    Article  PubMed  CAS  Google Scholar 

  • Zoller B., Garcia-de-Frutos P., and Dahlback B. (1998). A common 4G allele in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene as a risk factor for pulmonary embolism and arterial thrombosis in hereditary protein S deficiency.Thromb. Haemost. 79, 802–807.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratory for Pharmaceutical Biology, Katholieke Universiteit Leuven, Leuven, Belgium

    Ann Gils & Paul J. Declerck

Authors
  1. Ann Gils
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paul J. Declerck
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Biochemistry & Molecular Biology and Oncology, University of Calgary Health Sciences Centre, Calgary, Alberta, Canada

    David M. Waisman

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer Science+Business Media New York

About this chapter

Cite this chapter

Gils, A., Declerck, P.J. (2003). Plasminogen Activators Inhibitors. In: Waisman, D.M. (eds) Plasminogen: Structure, Activation, and Regulation. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-0165-7_3

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-0165-7_3

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-4949-5

  • Online ISBN: 978-1-4615-0165-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation